Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 19 December 2012 | By Alexander Gaffney, RAC,
A new draft guidance document published by the US Food and Drug Administration (FDA) is intended to assist sponsors in the application of electronic regulatory submissions for products regulated by the Center for Drug Evaluation and Research (CDER), part of an ongoing series of guidances meant to move the industry away from paper-based submissions.
CDER regulates nearly all pharmaceutical products, including branded and biologic medicines, as well as many biological products and some combination products, depending on their primary mechanism of action.
For a novel product, usually submitted in the form of either a new drug application (NDA) or a biologics licensing application (BLA), the center requires the submission of clinical data in order to show that it is both safe and efficacious before considering it for approval.
The point of the guidance, Providing Submissions in Electronic Format - Summary Level Clinical Site Data for CDER's Inspection Planning, "is to assist applicants in the submission of a clinical dataset that describes and summarizes the characteristics and outcomes of clinical investigations at the level of the individual study site (summary level clinical site data)," FDA explained.
That data, in turn, is intended to facilitate CDER's ability to take what regulators called a "risk-based approach" for conducting on-site inspections, which FDA says is necessary to evaluate the integrity of data submitted in support of an NDA or BLA. Inspected entities might include the institutional review board (IRB), the clinical investigation site, the contract research organization (CRO), the sponsor or the clinical investigators.
While this responsibility is not new, FDA said its increasingly tight deadlines under the new Prescription Drug User Fee Act (PDUFA) reauthorization mean that in order for it to meet its review performance goals, it must accomplish its duties to inspect even faster. "To facilitate timely selection of inspection sites, CDER must have sufficient data from the sponsor to identify which sites will provide the necessary information for the review of the application," FDA explained.
The present format of these data, FDA continued, is inefficient in that it presents the data at the subject, rather than site, level. "CDER has determined that to plan efficiently for clinical site inspections and to meet the PDUFA goal dates for marketing applications, CDER prefers to receive summary level clinical site data."
These data are typically submitted to CDER during the filing determination and review planning phases.
CDER said that it has already experimented with the submission of such data in a pilot program, and that the use of summary level clinical data has facilitated a "more efficient site selection" for inspections.
Under the new system, CDER said it "anticipates that site inspections will be conducted earlier in the review cycle," allowing for a faster and more efficient review by FDA, as well as more time and opportunities for sponsors to address regulatory issues earlier in the review process.
So what should the clinical data application include?
"A single summary level clinical site dataset should contain data from all major (e.g., pivotal) studies used to support safety and efficacy in the application, including studies with different treatment indications," FDA explains in the draft guidance. "For each major study used to support safety and efficacy, data should be submitted by clinical site and treatment arm for the intent-to-treat (ITT) population. For clinical investigator sites involved in multiple studies in support of an application, applicants should provide the data independently for each study within the dataset."
"When in doubt about what constitutes a 'major' study, applicants should consult the relevant review division," FDA concluded. Regulators said sponsors should refer to a number of other guidance documents for additional requirements related to the submission of clinical data.
Tags: Clinical Data, clinical trials, PDUFA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.